Carderock Capital Management Inc decreased Becton Dickinson & Co (BDX) stake by 21.19% reported in 2018Q4 SEC filing. Carderock Capital Management Inc sold 5,503 shares as Becton Dickinson & Co (BDX)’s stock rose 1.29%. The Carderock Capital Management Inc holds 20,465 shares with $4.61M value, down from 25,968 last quarter. Becton Dickinson & Co now has $68.32B valuation. The stock increased 0.66% or $1.66 during the last trading session, reaching $253.92. About 2.02M shares traded or 86.68% up from the average. Becton, Dickinson and Company (NYSE:BDX) has risen 15.93% since March 15, 2018 and is uptrending. It has outperformed by 11.56% the S&P500. Some Historical BDX News: 03/05/2018 – Becton Dickinson Raises FY18 Comparable, Currency-Neutral Rev Growth View to 5%-5.5%; 14/05/2018 – Cipher Capital Adds Occidental, Exits Becton Dickinson: 13F; 26/04/2018 – BD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types; 22/03/2018 – BD Updates lnstructions for Use for Certain BD Vacutainer® Blood Collection Tubes; 09/05/2018 – MANDATE: Becton, Dickinson and Co. EUR, GBP Bmark Bond Roadshow; 23/03/2018 – FDA: Becton Dickinson (BD) and Company Recalls Vacutainer® EDTA Blood Collection Tubes Due to Chemical Interference with; 28/04/2018 – FDA: Becton Dickinson & Co.- BD MAX DNA MMK Lab Use, catalog no. 442828; 22/03/2018 – BD Has Been Cooperating With FDA, Launched an Internal Investigation; 22/03/2018 – FDA: Becton Dickinson & Company- BD Vacutainer® EDTA Pink Top Tube; Catalog Numbers: 1. 367842 (UDI: 50382903678421); 2. 36789; 22/03/2018 – BD AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST
Inflarx N.V. (NASDAQ:IFRX) had an increase of 17.35% in short interest. IFRX’s SI was 443,000 shares in March as released by FINRA. Its up 17.35% from 377,500 shares previously. With 109,000 avg volume, 4 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 6.21%. The stock decreased 2.51% or $1.22 during the last trading session, reaching $47.4. About 283,960 shares traded or 148.84% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 15, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss EUR10.3M
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.22 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, also Nasdaq.com with their article: “Hydrogenics Reports Fourth Quarter and Full Year 2018 Results – Nasdaq” published on March 15, 2019, Nasdaq.com published: “Village Farmsâ€™ Cannabis Operation Achieves Profitability; Stock Pops 7% – Nasdaq” on March 14, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Globus Maritime Limited Reports Financial Results for the Quarter and Year Ended December 31, 2018 – Nasdaq” published on March 15, 2019 as well as Nasdaq.com‘s news article titled: “BCE Hits 52-Week High: What’s Driving the Outperformance? – Nasdaq” with publication date: March 14, 2019.
More news for Becton, Dickinson and Company (NYSE:BDX) were recently published by: Seekingalpha.com, which released: “FDA OK’s BD’s Venovo stent – Seeking Alpha” on March 14, 2019. Seekingalpha.com‘s article titled: “Why Hospitals Are Not Buying The T2 Biosystems Diagnostic System – $1.50 1-Year Price Target – Seeking Alpha” and published on March 05, 2019 is yet another important article.
Since November 7, 2018, it had 0 insider purchases, and 7 sales for $18.75 million activity. FORLENZA VINCENT A also sold $3.18M worth of Becton, Dickinson and Company (NYSE:BDX) on Wednesday, November 14. 5,189 shares were sold by Lim James C, worth $1.26M on Thursday, November 8. Bodner Charles R sold $511,328 worth of stock. 5,243 Becton, Dickinson and Company (NYSE:BDX) shares with value of $1.28M were sold by Polen Thomas E Jr. Mas Ribo Alberto had sold 4,530 shares worth $1.07M on Wednesday, November 14. Borzi James W had sold 5,887 shares worth $1.49 million. 42,000 Becton, Dickinson and Company (NYSE:BDX) shares with value of $9.96M were sold by RING TIMOTHY M.
Among 7 analysts covering Becton (NYSE:BDX), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Becton had 10 analyst reports since October 4, 2018 according to SRatingsIntel. On Wednesday, January 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm earned “Buy” rating on Tuesday, November 13 by Citigroup. The stock of Becton, Dickinson and Company (NYSE:BDX) earned “Buy” rating by Citigroup on Wednesday, January 2. As per Thursday, November 8, the company rating was maintained by KeyBanc Capital Markets. The rating was maintained by Morgan Stanley on Thursday, October 4 with “Equal-Weight”. The company was maintained on Friday, March 1 by Argus Research.
Investors sentiment increased to 0.91 in Q4 2018. Its up 0.01, from 0.9 in 2018Q3. It is positive, as 64 investors sold BDX shares while 391 reduced holdings. 98 funds opened positions while 315 raised stakes. 226.22 million shares or 4.12% more from 217.26 million shares in 2018Q3 were reported. 2,978 are owned by Woodmont Counsel Limited Com. Tiaa Cref Invest owns 772,616 shares for 0.14% of their portfolio. Pettyjohn Wood White Inc reported 2,578 shares or 0.21% of all its holdings. Hillsdale Investment Mgmt has 0% invested in Becton, Dickinson and Company (NYSE:BDX) for 12 shares. Foothills Asset accumulated 10,731 shares. Exane Derivatives holds 0% of its portfolio in Becton, Dickinson and Company (NYSE:BDX) for 2,221 shares. Eagle Ridge Investment Mngmt reported 1,640 shares stake. Btr Capital Mngmt Inc holds 1,729 shares. Peak Asset Mngmt Ltd Liability Co accumulated 3.4% or 40,207 shares. The New York-based Pinnacle Associate Ltd has invested 0.14% in Becton, Dickinson and Company (NYSE:BDX). Next Grp reported 556 shares stake. Assetmark has invested 0% in Becton, Dickinson and Company (NYSE:BDX). Employees Retirement System Of Texas invested in 0.14% or 40,003 shares. Advisory Services Net has 16,286 shares. Barbara Oil, a Illinois-based fund reported 5,000 shares.
Analysts await Becton, Dickinson and Company (NYSE:BDX) to report earnings on May, 2. They expect $2.59 EPS, down 2.26% or $0.06 from last year’s $2.65 per share. BDX’s profit will be $696.87 million for 24.51 P/E if the $2.59 EPS becomes a reality. After $2.70 actual EPS reported by Becton, Dickinson and Company for the previous quarter, Wall Street now forecasts -4.07% negative EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.